Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929

This publication has 23 references indexed in Scilit:

• PARP inhibitor plus radiotherapy reshapes an inflamed tumor microenvironment that sensitizes small cell lung cancer to the anti-PD-1 immunotherapy
  Cancer Letters, 2022
• Olaparib as maintenance treatment in patients with chemosensitive small cell lung cancer (STOMP): A randomised, double-blind, placebo-controlled phase II trial
  Lung Cancer, 2022
• Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer
  British Journal of Cancer, 2022
• Schlafen 11 predicts response to platinum-based chemotherapy in gastric cancers
  British Journal of Cancer, 2021
• Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
  Cancer Cell, 2021
• Olaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivo
  Journal of Cancer Research and Clinical Oncology, 2020
• Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
  The Lancet, 2019
• First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
  New England Journal of Medicine, 2018
• SLFN11 Blocks Stressed Replication Forks Independently of ATR
  Molecular Cell, 2018
• Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer—what limits limited disease?
  Lung Cancer, 2002